|
AU2014202556A1
|
|
Immunotherapy targeting intracellular pathogens
|
|
AU2014200368A1
|
|
Immunogenic peptides and their use in immune disorders
|
|
AU2013263773A1
|
|
Elimination of immune responses to viral vectors
|
|
GB201122342D0
|
|
Monocyte biomarkers for cancer detection
|
|
AU2010206143A1
|
|
PHD2 inhibition for blood vessel normalization, and uses thereof
|
|
WO2009101208A2
|
|
Immunotherapy targeting intracellular pathogens
|
|
EP2245059A1
|
|
Cd4+ t-cells with cytolytic properties
|
|
EP2623115A1
|
|
Immunogenic control of tumours and tumour cells
|
|
EP2623125A1
|
|
Elimination of immune responses to viral vectors
|
|
US2010322967A1
|
|
B cell tolerance induction
|
|
CA2715517A1
|
|
Immunogenic peptides and their use in preventing or treating allograft rejection
|
|
CA2660605A1
|
|
Immunogenic peptides and their use in allergic and autoimmune disorders
|
|
EP1910420A2
|
|
Human inhibitory anti-factor viii antibodies binding to the a2 domain
|
|
US2007027100A1
|
|
Use of placental growth factor for treating ischemic muscle disease
|
|
US2006115474A1
|
|
Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
|
|
EP1222929A2
|
|
Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
|
